Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Change in Acquisitions & Divestments (2016 - 2025)

Tg Therapeutics has reported Change in Acquisitions & Divestments over the past 5 years, most recently at $30.0 million for Q4 2025.

  • Quarterly results put Change in Acquisitions & Divestments at $30.0 million for Q4 2025, down 59.29% from a year ago — trailing twelve months through Dec 2025 was $237.5 million (down 23.61% YoY), and the annual figure for FY2025 was $237.5 million, down 23.61%.
  • Change in Acquisitions & Divestments for Q4 2025 was $30.0 million at Tg Therapeutics, down from $77.8 million in the prior quarter.
  • Over the last five years, Change in Acquisitions & Divestments for TGTX hit a ceiling of $92.3 million in Q3 2024 and a floor of $16.0 million in Q1 2023.
  • Median Change in Acquisitions & Divestments over the past 4 years was $49.3 million (2025), compared with a mean of $51.1 million.
  • Biggest five-year swings in Change in Acquisitions & Divestments: surged 358.76% in 2024 and later crashed 59.29% in 2025.
  • Tg Therapeutics' Change in Acquisitions & Divestments stood at $20.3 million in 2022, then increased by 16.81% to $23.7 million in 2023, then soared by 211.26% to $73.7 million in 2024, then plummeted by 59.29% to $30.0 million in 2025.
  • The last three reported values for Change in Acquisitions & Divestments were $30.0 million (Q4 2025), $77.8 million (Q3 2025), and $49.3 million (Q2 2025) per Business Quant data.